Release Date: January 3, 2011
National Institute of Allergy and Infectious Diseases (NIAID)
The purpose of this Notice is to announce a substantive
change to requirements articulated in PAR-10-184:
NIAID Clinical Trial Implementation Grant (R01).
In Section I, 1. Research Objectives, the "Scope" section of PAR-10-184:
Delete "include a randomized design" from the sentence that reads: "The trial must be hypothesis- driven, include a randomized design, and have clear primary and secondary endpoints."
Randomization is only required for those trials for which it is an appropriate element of trial design.
All other aspects of PAR-10-184 remain unchanged.
Please direct all inquiries to:
Anna Ramsey-Ewing, Ph.D.
Associate Director for Extramural Science Policy
Office of the Director
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
6700-B Rockledge Drive, MSC 7610
Bethesda, MD 20892-7610
Phone: (301) 435-8536
FAX: (301) 402-0369
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.